Finasteride has been the standard medical treatment for androgenetic alopecia since the FDA approved the oral 1mg tablet in 1997. For most of that time, there was only one way to take it: swallow a pill. Topical formulations have changed that equation. Compounding pharmacies now produce finasteride solutions and gels applied directly to the scalp, promising similar hair growth with lower systemic exposure. The question most people are trying to answer is straightforward: does topical work as well as oral, and does it actually reduce side effects? The clinical data is finally catching up to the marketing. Tracking your response with consistent photos through BaldingAI is the clearest way to see which formulation is working for your specific pattern.
TL;DR
- Oral finasteride 1mg reduces serum DHT by approximately 70%. Topical formulations reduce serum DHT by roughly 30-40%, depending on concentration.
- A 2022 JAMA Dermatology study found topical 0.25% finasteride non-inferior to oral 1mg for hair count improvement at 24 weeks.
- Sexual side effects were reported at 1.4% with topical vs. 3.6% with oral in one comparative trial.
- Topical finasteride is available through compounding pharmacies but is not FDA-approved as a standalone product for hair loss.
- Both formulations require 3-6 months minimum before meaningful results are visible. Tracking is essential regardless of which you choose.
Important
This article is educational and not medical advice. If you are worried about sudden shedding, scalp symptoms, or side effects, talk to a licensed clinician.
How oral finasteride works (quick recap)
Oral finasteride inhibits type II 5-alpha reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT) in the scalp, prostate, and other tissues. At 1mg daily, it reduces circulating serum DHT by approximately 70%. This systemic reduction is why it works so well for hair loss: less DHT reaching the follicle means less miniaturization over time. If you want the full breakdown of what to expect on oral finasteride, the finasteride timeline guide covers each phase in detail.
The problem is that 70% systemic DHT reduction affects every tissue in the body, not just the scalp. DHT plays roles in sexual function, neurosteroid production, and other processes. This whole-body effect is the root of the side effect profile that makes some men hesitant to start or continue the medication.
How topical finasteride is different
Topical finasteride is applied directly to the scalp as a solution, spray, or gel, typically at concentrations of 0.1% or 0.25%. The idea is to deliver a therapeutic dose of the drug directly to the follicles while limiting how much enters the bloodstream. Since the drug goes straight to the target tissue, you need less total finasteride to achieve meaningful DHT reduction at the scalp level.
Pharmacokinetic studies confirm the theory holds up. Topical formulations reduce scalp DHT significantly (some studies show comparable scalp tissue levels to oral dosing) while only reducing serum DHT by 30-40%. Compare that to the 70% serum reduction from oral finasteride. The gap between scalp-level and systemic DHT suppression is the entire rationale for going topical.
What the clinical data shows
The most cited head-to-head trial is Piraccini et al. (2022), published in JAMA Dermatology. This randomized, double-blind study compared topical finasteride 0.25% with oral finasteride 1mg over 24 weeks. The primary endpoint was change in target area hair count. The result: topical 0.25% was non-inferior to oral 1mg. Both groups showed statistically significant increases in hair count from baseline, with no meaningful difference between the two.
An earlier phase II study (Caserini et al., 2014) tested multiple topical concentrations and found that 0.25% topical finasteride produced scalp DHT reductions comparable to oral 1mg while keeping serum DHT reduction in the 30-40% range. The 0.1% concentration also showed benefit but with slightly less consistent scalp DHT suppression.
These are encouraging results, but context matters. Most topical finasteride studies have relatively short follow-up periods (6 to 12 months). Oral finasteride has decades of long-term data. We know oral finasteride maintains efficacy for 5+ years with continued use. The long-term durability of topical formulations is plausible based on the mechanism of action but not yet proven in the same way.
Side effect comparison
This is where most people's interest sharpens. The sexual side effects of finasteride (decreased libido, erectile difficulty, reduced ejaculate volume) are reported by a small but real percentage of users. In placebo- controlled trials, oral finasteride 1mg shows sexual side effects in roughly 2-4% of participants, with some trials reporting up to 3.6%.
The Piraccini et al. trial reported sexual adverse events at 1.4% in the topical group vs. 3.6% in the oral group. Other studies have reported similar trends: lower rates of sexual side effects with topical formulations. The logical explanation is the reduced systemic DHT suppression. When serum DHT drops only 30-40% instead of 70%, the tissues that depend on DHT for normal function are less affected.
Important caveat: topical finasteride is not zero-systemic. Some of the drug absorbs through the scalp and enters the bloodstream. The 30-40% serum DHT reduction proves this. Men who are extremely sensitive to any DHT suppression may still experience side effects on topical formulations. "Topical" does not mean "local only."
Practical considerations: availability, cost, and consistency
Oral finasteride is FDA-approved, generic, and available at nearly every pharmacy for roughly $10-30 per month. You take one pill daily. Compliance is simple.
Topical finasteride is not FDA-approved as a standalone hair loss product. It is available through compounding pharmacies and telehealth platforms that specialize in hair loss. Prices vary widely, typically $40-90 per month depending on the provider and concentration. Insurance coverage is inconsistent. Some formulations combine topical finasteride with minoxidil in a single solution, which can simplify the routine but makes it harder to attribute results to either ingredient independently.
Application consistency is a real factor. Oral finasteride takes 5 seconds. Topical application requires parting the hair, applying the solution to the scalp (not the hair), and allowing it to dry. For men with longer hair, this takes more effort. If you know compliance is a challenge for you, factor that into the decision. A treatment you skip three times a week is less effective than one you take daily.
Who should consider switching from oral to topical?
The most common scenario is a man who responds well to oral finasteride (stable or improved hair density) but experiences side effects he wants to reduce. Switching to topical preserves scalp-level DHT inhibition while lowering systemic exposure. The finasteride decision checklist can help structure this evaluation before you talk to your prescriber.
Men who have never taken finasteride and want to minimize systemic exposure from the start are also reasonable candidates for topical. The Piraccini data suggests they will not sacrifice efficacy at the 0.25% concentration. The tradeoff is higher cost, less long-term data, and a more involved daily routine.
Men considering the broader DHT-blocking landscape might also weigh dutasteride vs. finasteride before deciding on formulation. Dutasteride inhibits both type I and type II 5-alpha reductase, producing greater total DHT reduction. A topical dutasteride option is also in early clinical investigation, though it is further behind in the evidence base.
The timeline is the same: 3-6 months minimum
Both formulations work within the same biology. Hair follicles cycle over months, not days. Both formulations require a minimum of 3 months before early changes become detectable and 6 to 12 months for a full assessment. Switching formulations resets this clock partially, because you need time to confirm the new delivery method is producing adequate scalp-level DHT reduction for your follicles specifically.
This is exactly where tracking becomes non-negotiable. "I feel like it's working" is not data. Consistent photos taken at the same angles, in the same lighting, at regular intervals give you an objective record of what is happening. BaldingAI's zone-based capture system is designed for this: baseline photos before starting, then 4-8 week comparison windows that show real trends instead of single-session impressions.
If you are switching from oral to topical, your tracking data from the oral phase becomes your new baseline. You already know what your hair looks like under treatment. Now you are testing whether a different delivery method holds that line. Without before-and-after data on both sides of the switch, you are guessing.
The bottom line
Topical finasteride is a legitimate option, not a gimmick. The head- to-head data shows comparable efficacy to oral finasteride at the 0.25% concentration with a lower rate of sexual side effects. It costs more, requires more effort to apply, and has less long-term data. For men who want effective DHT inhibition at the scalp without the full systemic suppression of oral dosing, topical fills a real gap.
Whichever formulation you use, the approach stays the same. Set a baseline, track consistently, compare windows of 4-8 weeks, and make decisions based on what the data shows rather than what the mirror looks like on any single morning.
Related reading: finasteride timeline expectations and how to track your response.
Sources: Piraccini et al. (2022) JAMA Dermatology, Caserini et al. (2014).
